Company news
Enliven Therapeutics, Inc. news in 2022
Enliven Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Enliven Therapeutics and Imara Announce Merger Agreement
October 12, 2022
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
April 4, 2022
Imara Reports Full Year 2021 Financial Results and Business Highlights
March 14, 2022
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
March 7, 2022
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
February 9, 2022
Imara Announces FDA Clearance of Investigational New Drug Application (IND) for Tovinontrine (IMR-687) for Heart Failure with Preserved Ejection Fraction (HFpEF)
January 24, 2022
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
January 4, 2022
Calls in 2022
Decks in 2022
- IMARA — Merger or Acquisition (October 2022)
Merger or acquisition · 45 slides · Oct 13, 2022